The treatment of recurrent or metastatic cervical cancer remains challenging due to low efficacy of most chemotherapy agents. The recent FDA approval of pembrolizumab and tisotumab have broadened the therapeutic options available to our patients. Our panelists review KEYNOTE-826 to discuss the role of pembrolizumab and the inclusion of bevacizumab, as well as the combination of immunotherapy and radiation in the GOG-9929 trial. 

Speakers:
C. Trey Leath, MD
University of Alabama at Birmingham

Jyoti Mayadev, MD
University of California San Diego

Leslie Randall, MD
Virginia Commonwealth University

Renata Urban, MD (moderator)
University of Washington

Christine Walsh, MD (moderator)
University of Colorado


Recorded on December 13, 2021. 

Keywords: Journal club, cervix, cervical cancer, immunotherapy, pembrolizumab, ipilimumab, clinical trial, trial design